• Anasayfa
  • Hakkında
  • Politika
  • İletişim
    • English
    • Türkçe
  • Türkçe 
    • English
    • Türkçe
  • Giriş
Gelişmiş Arama
Öğe Göster 
  •   Ana Sayfa
  • Tüm Akademik Yayınlar
  • Yayınlar - Eserler
  • Öğe Göster
  •   Ana Sayfa
  • Tüm Akademik Yayınlar
  • Yayınlar - Eserler
  • Öğe Göster
JavaScript is disabled for your browser. Some features of this site may not work without it.

Outcome of Daily Cisplatin with Thoracic Chemoradiotherapy in Advanced Non-small Cell Lung Cancer Patients with Comorbid Disorders: a Pilot Study

Thumbnail
Göster/Aç
20-10.7314-apjcp.2014.15.20.8591.pdf (400.8Kb)
Tarih
2014-01-01
Yazar
Kiziltan, HURİYE ŞENAY
Bayir, Ayse Gunes
TAŞTEKİN, Didem
Coban, GANİME
Eris, ALİ HİKMET
Aydin, TEOMAN
MAYADAGLI, Alparslan
Danışman
Türü
Article
Üst veri
Tüm öğe kaydını göster
Özet
Background: Lung cancer is the most common cancer in males worldwide. The principal mode of treatment in the early stage of non-small cell lung cancer (NSCLC) is surgery. However, five-year survival is only about 15% for all stages. The aim is to investigate the effect of daily low dose cisplatin concurrently with radiation therapy in advanced NSCLC patients with poor performance status. Materials and Methods: Ten patients diagnosed as inoperable Stage IIIB NSCLC with comorbid disease were assessed retrospectively in Bezmialem Vakif University, Faculty of Medicine, Department of Radiation Oncology, between 2011 to 2013. ECOG performance status was between 3 and 4. Cisplatin was administered at 6mg/m2 daily, for 5 days a week concurrently with radiotherapy using 160-200 cGy daily fractions, 54 Gy being the lowest and 63 Gy being the highest dose. Results: Complete response at the primary tumour site was obtained in 20% patients. Grade I esophagitis was seen 70 percent of patients, and the grade II haematological toxicity rate was 20 %. Median survival time was 7 months. Conclusions: Median survival time was reasonable, despite the patients ECOG performance status of 3-4, which is similar to groups even without comorbid disorders in comparison to other published papers in the literature. Acceptable toxicity, high response rates and quality of life of patients are the other favourable features.
Konu
Kiziltan H. Ş. , Bayir A. G. , TAŞTEKİN D., Coban G., Eris A. H. , Aydin T., MAYADAGLI A., -Outcome of Daily Cisplatin with Thoracic Chemoradiotherapy in Advanced Non-small Cell Lung Cancer Patients with Comorbid Disorders: a Pilot Study-, ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, cilt.15, ss.8591-8594, 2014
Bağlantı
https://hdl.handle.net/20.500.12645/2976
Koleksiyonlar
  • PubMed İndeksli Yayın Koleksiyonu
  • Sağlık Hizmetleri Meslek Yüksekokulu
  • Scopus İndeksli Yayınlar Koleksiyonu
  • WoS İndeksli Yayınlar Koleksiyonu
  • Yayınlar - Eserler

BEZMIALEM VAKIF UNIVERSITY

About us |Policies | Library | Contact us | Send Feedback | Sitemap | Admin

Bezmialem Vakıf Üniversitesi, Adnan Menderes Bulvarı Vatan Caddesi 34093 Fatih, İstanbul / TURKEY
Copyright © Bezmialem Vakıf Üniversitesi

Creative Commons Lisansı
Bezmialem Institutional Repository, Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.

OpenAccess@BVU

Support by  UNIREPOS






sherpa/romeo

Göz at

Tüm DSpaceBölümler & KoleksiyonlarTarihe GöreYazara GöreBaşlığa GöreKonuya GöreTüre göreDile göreErişim Hakkına göreDanışmana göreKurum Yazarına göreBu KoleksiyonTarihe GöreYazara GöreBaşlığa GöreKonuya GöreTüre göreDile göreErişim Hakkına göreDanışmana göreKurum Yazarına göre

Hesabım

GirişKayıt

BEZMIALEM VAKIF UNIVERSITY

About us |Policies | Library | Contact us | Send Feedback | Sitemap | Admin

Bezmialem Vakıf Üniversitesi, Adnan Menderes Bulvarı Vatan Caddesi 34093 Fatih, İstanbul / TURKEY
Copyright © Bezmialem Vakıf Üniversitesi

Creative Commons Lisansı
Bezmialem Institutional Repository, Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.

OpenAccess@BVU

Support by  UNIREPOS